Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Rivian cuts jobs amid EV credit expiry, prepares to launch lower-priced R2 SUV.
Super Micro Computer reports revenue miss, but secures $12B in AI design wins, reaffirming strong fiscal year forecast amid the AI boom.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Rivian cuts jobs amid EV credit expiry, prepares to launch lower-priced R2 SUV.
Super Micro Computer reports revenue miss, but secures $12B in AI design wins, reaffirming strong fiscal year forecast amid the AI boom.